Press Releases

Date Title
10/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/26/22 Sarepta Therapeutics anuncia los beneficiarios de la Entrega Inaugural de Subvenciones para LGMD; el programa apoya los esfuerzos innovadores para acortar el recorrido hasta el diagnóstico
10/26/22 Sarepta Therapeutics Announces Recipients of Inaugural LGMD Grant Awards; Program Supports Innovative Efforts to Shorten the Diagnostic Journey
10/26/22 Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
10/7/22 Sarepta Therapeutics Presents New Data from its Gene Therapy and RNA Platforms at World Muscle Society 2022
9/30/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/29/22 Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
9/14/22 Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
9/12/22 Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027
9/7/22 Sarepta Therapeutics Anuncia a los Destinatarios de Route 79, el Programa de Becas de Duchenne, para el Año Académico 2022-2023
Displaying 61 - 70 of 812